围术期阿司匹林与冠状动脉旁路移植术:随机对照试验的更新荟萃分析
结果显示继续阿司匹林组与停药组在全因死亡率、围术期心肌梗死和术后失血量上均无显著差异,低剂量与大剂量阿司匹林之间也无显著差异。
要点
- 冠脉搭桥术前继续阿司匹林不显著增加全因死亡、围术期心梗或术后失血风险
- 低剂量与较大剂量阿司匹林在结局上无显著差异
- 纳入研究方法学质量偏低,结论需谨慎解读
核心结论
- 冠状动脉旁路移植术前继续与停用阿司匹林在全因死亡率、围术期心肌梗死和术后出血风险上无显著差异。
主要发现
- 低剂量与较大剂量阿司匹林之间无显著差异。
临床怎么用
- 冠脉搭桥术前是否继续阿司匹林需个体化权衡血栓与出血风险。
- 低剂量阿司匹林与较大剂量在围术期结局上无显著差异。
局限性
- 纳入研究根据Cochrane随机试验偏倚风险工具评价为低方法学质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The decision to continue aspirin before elective coronary artery bypass graft surgery remains contentious because of competing thrombotic and bleeding risks. We performed a contemporary systematic review and meta-analysis to compare outcomes between patients undergoing coronary artery bypass grafting who stopped and continued aspirin before surgery. METHODS: PubMed, MEDLINE, and CENTRAL databases were searched from inception to 4 October 2023 for randomized controlled trials comparing patients undergoing coronary artery bypass grafting who continued preoperative aspirin with those who discontinued before surgery. Studies with cointervention arms and multivariable-adjusted or propensity matched observational studies were excluded. Summary odds ratios were calculated using a random effects model for dichotomous and continuous variables. Subgroup and sensitivity analyses were conducted in order to explore sources of heterogeneity. RESULTS: Fifteen eligible randomized controlled trials were included with a total of 6,188 patients. Patients who continued aspirin demonstrated no significant difference in all-cause mortality (odds ratio, 1.37; confidence interval, 0.81-2.33), perioperative myocardial infarction (odds ratio, 0.81; confidence interval, 0.55-1.18), and postoperative blood loss (mean difference, 66.12 mL; confidence interval, -1.45 to 133.69). No significant difference was observed between low-dose and greater doses of aspirin. There was minimal heterogeneity amongst included studies (I2 = 0%, P = .97, I2 = 33%, P = .13, and I2= 76, P = .06, respectively). Studies were of low methodologic quality according to Cochrane Risk of Bias for Randomized Trials. CONCLUSIONS: This largest to-date systematic review and meta-analysis found no significant difference for risk of all-cause mortality, perioperative myocardial infarction, and postoperative bleeding between patients continuing and stopping aspirin before coronary artery bypass grafting.
引用
- Gupta AK, Zaka A, Lombardo A, et al. Perioperative aspirin and coronary artery bypass graft surgery: An updated meta-analysis of randomized controlled trials. Surgery. 2024. PMID: 39708413. doi:10.1016/j.surg.2024.109003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。